NAMSW
NewAmsterdam Pharma Company N.V.
Set alert
- YTD
- -60.94%
- 1 year
- -67.09%
- Open
- 24.41
- Prev close
- 10.75
- Mkt cap
- 2.25B
- Vol
- 2.41K
- Avg vol
- 1.20K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.68
- High
- 9.23
- Forward P/E
- 0.00
- Beta
- 0.10
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 12.22
- 200-d avg
- 19.03
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.62
- EPS (TTM)
- 0.00
- Beta
- 0.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 7.12M
- Revenue growth
- -80.70%
- Free cash flow
- -45.36M
- Total cash
- 633.85M
- Total debt
- 82.00K
- Return on equity
- -36.81%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 12.22
- 200-day average
- 19.03
Analyst view
Consensus: none
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.49491 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -0.47702 | -0.52 | -0.04 | -9.01% |
| May 7, 2026 | Mar 31, 2026 | -0.45897 | -0.40 | +0.06 | +12.85% |
| Feb 18, 2026 | Dec 31, 2025 | -0.45375 | -0.62 | -0.17 | -36.64% |
| Nov 5, 2025 | Sep 30, 2025 | -0.39095 | -0.60508 | -0.21 | -54.77% |
| Aug 6, 2025 | Jun 30, 2025 | -0.46317 | -0.18402 | +0.28 | +60.27% |
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
- Country
- Netherlands
- Website
- newamsterdampharma.com
News
Your note
Sign in to keep a note on NAMSW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 10.88% | 500,333 | 4.34M | Jun 29, 2026 |
| RA Capital Management, L.P. | 7.25% | 333,333 | 2.89M | Jun 29, 2026 |
| Affinity Asset Advisors, Llc | 5.33% | 245,000 | 2.13M | Jun 29, 2026 |
| Bain Capital Life Sciences Investors, LLC | 2.17% | 99,999 | 867.99K | Jun 29, 2026 |
| Deerfield Management Company, L.P | 2.02% | 92,787 | 805.39K | Jun 29, 2026 |
| Aristeia Capital, LLC | 0.34% | 15,708 | 136.34K | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| JNL Series Trust-JNL/Westchester Capital Event Driven Fund | 0.14% | 6,630 | 57.55K | Dec 30, 2023 |